Overall, we have shown that hepatic LAL overexpression is unable to prevent the development of NAFLD on a Western diet, providing evidence against using recombinant LAL as a potential treatment for NAFLD. Here, LIPA is linked to metabolic dysfunction-associated steatotic liver disease.